These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24840269)

  • 1. Overcoming toxicity and side-effects of lipid-lowering therapies.
    Wilkinson MJ; Laffin LJ; Davidson MH
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):439-52. PubMed ID: 24840269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin safety: an overview and assessment of the data--2005.
    Bays H
    Am J Cardiol; 2006 Apr; 97(8A):6C-26C. PubMed ID: 16581330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
    Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
    Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How well tolerated are lipid-lowering drugs?
    Tomlinson B; Chan P; Lan W
    Drugs Aging; 2001; 18(9):665-83. PubMed ID: 11599634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are statins really wonder drugs?
    Grover HS; Luthra S; Maroo S
    J Formos Med Assoc; 2014 Dec; 113(12):892-8. PubMed ID: 24231094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing statin adverse effects in the clinic: the 5 Ms.
    Katz DH; Intwala SS; Stone NJ
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):533-42. PubMed ID: 24770611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Options for Statin-Associated Muscle Symptoms.
    Laufs U; Scharnagl H; Halle M; Windler E; Endres M; März W
    Dtsch Arztebl Int; 2015 Oct; 112(44):748-55. PubMed ID: 26575138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
    Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
    Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin intolerance: now a solved problem.
    Sikka P; Kapoor S; Bindra VK; Sharma M; Vishwakarma P; Saxena KK
    J Postgrad Med; 2011; 57(4):321-8. PubMed ID: 22120862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statin intolerance].
    Tonstad S
    Tidsskr Nor Laegeforen; 2017 Jan; 137(1):36-38. PubMed ID: 28073228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of statin-induced myopathy and perspectives for the future.
    Nikolic D; Banach M; Chianetta R; Luzzu LM; Pantea Stoian A; Diaconu CC; Citarrella R; Montalto G; Rizzo M
    Expert Opin Drug Saf; 2020 May; 19(5):601-615. PubMed ID: 32233708
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
    Geng Q; Ren J; Chen H; Lee C; Liang W
    Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Statin myopathy--rarity or reality?].
    Pella D
    Vnitr Lek; 2010 Sep; 56(9 Suppl):972-6. PubMed ID: 21137170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of lipid lowering therapy on liver function].
    Paragh G; Fülöp P
    Orv Hetil; 2009 Jun; 150(26):1205-12. PubMed ID: 19546077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing statin-induced muscle toxicity in a lipid clinic.
    Blaier O; Lishner M; Elis A
    J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?
    Cornier MA; Eckel RH
    Curr Atheroscler Rep; 2015; 17(2):475. PubMed ID: 25432858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing the underestimated risk of statin-associated myopathy.
    Rallidis LS; Fountoulaki K; Anastasiou-Nana M
    Int J Cardiol; 2012 Sep; 159(3):169-76. PubMed ID: 21813193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.